Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
979
datasets available to search
ShareScore release 0.9.0
Dataset results
979 results for “HR”
To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor
ClinicalTrials.gov study NCT07358377. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
ClinicalTrials.gov study NCT02053545. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy
ClinicalTrials.gov study NCT06957379. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.
ClinicalTrials.gov study NCT04852081. IPD Sharing: NO. Countries: 1. Publications: 0.
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
ClinicalTrials.gov study NCT06081959. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
ClinicalTrials.gov study NCT04337658. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer
ClinicalTrials.gov study NCT04872985. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
ClinicalTrials.gov study NCT05759572. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer
ClinicalTrials.gov study NCT05963997. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors
ClinicalTrials.gov study NCT07257484. IPD Sharing: NO. Countries: 1. Publications: 0.
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
ClinicalTrials.gov study NCT05708235. IPD Sharing: NO. Countries: 2. Publications: 0.
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in HR Positive/HER2 Low Breast Cancer
ClinicalTrials.gov study NCT06340230. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations
ClinicalTrials.gov study NCT03009682. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer
ClinicalTrials.gov study NCT06276868. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Pro
ClinicalTrials.gov study NCT07281833. IPD Sharing: NO. Countries: 3. Publications: 0.
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
ClinicalTrials.gov study NCT04603183. IPD Sharing: NO. Countries: 3. Publications: 0.
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
ClinicalTrials.gov study NCT05891093. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer
ClinicalTrials.gov study NCT06207734. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
ClinicalTrials.gov study NCT06211764. IPD Sharing: YES. Countries: 14. Publications: 0.
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
ClinicalTrials.gov study NCT06642545. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.